Nina Raben

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 7

Top Topics

Tyrosine Kinase

Body Mass Index

Replacement Therapy

Top Venues

Clinical and translational medicine

Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics

EMBO molecular medicine

Chemical science

This page only lists publications with an associated author ORCID identifier.

Publications

Naresh K Meena, Yeap Ng, Davide Randazzo, Roberto Weigert, Rosa Puertollano, Nina Raben
Intravital imaging of muscle damage and response to therapy in a model of Pompe disease. Clinical and translational medicine 14 (3) (2024)
Naresh K Meena, Yeap Ng, Davide Randazzo, Roberto Weigert, Rosa Puertollano, Nina Raben
Intravital imaging of muscle damage and response to therapy in a model of Pompe disease. Clinical and translational medicine 14 (3) (2024)
Naresh K Meena, Yeap Ng, Davide Randazzo, Roberto Weigert, Rosa Puertollano, Nina Raben
Intravital imaging of muscle damage and response to therapy in a model of Pompe disease. Clinical and translational medicine 14 (3) (2024)
Naresh K Meena, Yeap Ng, Davide Randazzo, Roberto Weigert, Rosa Puertollano, Nina Raben
Intravital imaging of muscle damage and response to therapy in a model of Pompe disease. Clinical and translational medicine 14 (3) (2024)
Xiao Zhang, Huiying Liu, Naresh Meena, Chao Li, Guanghui Zong, Nina Raben, Rosa Puertollano, Lai-Xi Wang
Chemoenzymatic glycan-selective remodeling of a therapeutic lysosomal enzyme with high-affinity M6P-glycan ligands. Enzyme substrate specificity is the name of the game. Chemical science 12 (37) (2021)
Lara Kohler, Rosa Puertollano, Nina Raben
Pompe Disease: From Basic Science to Therapy. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 15 (4) (2019)
Jeong-A Lim, Lishu Li, Orian S Shirihai, Kyle M Trudeau, Rosa Puertollano, Nina Raben
Modulation of mTOR signaling as a strategy for the treatment of Pompe disease. EMBO molecular medicine 9 (3) (2017)